

Manuel Rodríguez-Perálvarez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3255140/publications.pdf>

Version: 2024-02-01

45
papers

2,126
citations

361413

20
h-index

254184

43
g-index

46
all docs

46
docs citations

46
times ranked

3403
citing authors

#	ARTICLE	IF	CITATIONS
1	A Systematic Review of Microvascular Invasion in Hepatocellular Carcinoma: Diagnostic and Prognostic Variability. <i>Annals of Surgical Oncology</i> , 2013, 20, 325-339.	1.5	486
2	Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients. <i>Journal of Hepatology</i> , 2021, 74, 148-155.	3.7	261
3	Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2013, 59, 1193-1199.	3.7	184
4	Tacrolimus Trough Levels, Rejection and Renal Impairment in Liver Transplantation: A Systematic Review and Meta-Analysis. <i>American Journal of Transplantation</i> , 2012, 12, 2797-2814.	4.7	137
5	Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2015, 19, 1-410.	2.8	130
6	Early tacrolimus exposure after liver transplantation: Relationship with moderate/severe acute rejection and long-term outcome. <i>Journal of Hepatology</i> , 2013, 58, 262-270.	3.7	99
7	Liver transplantation. <i>Current Opinion in Organ Transplantation</i> , 2014, 19, 253-260.	1.6	89
8	Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1266.	4.1	77
9	Biopsy-proven acute cellular rejection as an efficacy endpoint of randomized trials in liver transplantation: a systematic review and critical appraisal. <i>Transplant International</i> , 2016, 29, 961-973.	1.6	57
10	Predicting severity and clinical course of acute rejection after liver transplantation using blood eosinophil count. <i>Transplant International</i> , 2012, 25, 555-563.	1.6	52
11	Role of serum cytokine profile in ulcerative colitis assessment. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1864-1871.	1.9	49
12	Inflammation-based scores do not predict post-transplant recurrence of hepatocellular carcinoma in patients within milan criteria. <i>Liver Transplantation</i> , 2014, 20, 1327-1335.	2.4	37
13	Maintenance immunosuppression for adults undergoing liver transplantation: a network meta-analysis. <i>The Cochrane Library</i> , 2017, 2017, CD011639.	2.8	35
14	Changes in humoral immune response after SARS-CoV-2 infection in liver transplant recipients compared to immunocompetent patients. <i>American Journal of Transplantation</i> , 2021, 21, 2876-2884.	4.7	32
15	Impact of Early Initiated Everolimus on the Recurrence of Hepatocellular Carcinoma After Liver Transplantation. <i>Transplantation</i> , 2018, 102, 2056-2064.	1.0	31
16	Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation. <i>American Journal of Transplantation</i> , 2022, 22, 1671-1682.	4.7	31
17	Lack of agreement for defining "clinical suspicion of rejection" in liver transplantation: a model to select candidates for liver biopsy. <i>Transplant International</i> , 2015, 28, 455-464.	1.6	29
18	Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation. <i>World Journal of Hepatology</i> , 2015, 7, 649.	2.0	29

#	ARTICLE	IF	CITATIONS
19	Biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility. <i>Hepatic Medicine: Evidence and Research</i> , 2015, 7, 1.	2.5	25
20	Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria. <i>Journal of Hepatocellular Carcinoma</i> , 2018, Volume 6, 1-10.	3.7	22
21	The role of bronchoscopy in patients with SARS-CoV-2 pneumonia. <i>ERJ Open Research</i> , 2021, 7, 00165-2021.	2.6	21
22	Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes. <i>Gut</i> , 2014, 63, 1005-1013.	12.1	18
23	Cardiovascular morbidity and mortality is increased post-liver transplantation even in recipients with no pre-existing risk factors. <i>Liver International</i> , 2019, 39, 1557-1565.	3.9	18
24	Incidental hepatocellular carcinoma after liver transplantation: Prevalence, histopathological features and prognostic impact. <i>PLoS ONE</i> , 2017, 12, e0175010.	2.5	17
25	Area Under Trough Concentrations of Tacrolimus as a Predictor of Progressive Renal Impairment After Liver Transplantation. <i>Transplantation</i> , 2019, 103, 2539-2548.	1.0	17
26	Modulating immunosuppression in liver transplant patients with COVID-19. <i>Gut</i> , 2021, 70, 1412-1414.	12.1	16
27	GCDCA down-regulates gene expression by increasing Sp1 binding to the NOS-3 promoter in an oxidative stress dependent manner. <i>Biochemical Pharmacology</i> , 2015, 96, 39-51.	4.4	14
28	An objective definition for clinical suspicion of T-cell-mediated rejection after liver transplantation. <i>Clinical Transplantation</i> , 2017, 31, e13005.	1.6	13
29	Clearance of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Undergoing Surgical Resection or Liver Transplantation. <i>Cancers</i> , 2021, 13, 2476.	3.7	13
30	mTOR Expression in Liver Transplant Candidates with Hepatocellular Carcinoma: Impact on Histological Features and Tumour Recurrence. <i>International Journal of Molecular Sciences</i> , 2019, 20, 336.	4.1	11
31	Reducing Early Exposure to Calcineurin Inhibitors: The Key Factor for a Successful Renal Sparing Strategy. <i>American Journal of Transplantation</i> , 2013, 13, 239.	4.7	10
32	Circulating Tumor Cells in Hepatocellular Carcinoma: A Comprehensive Review and Critical Appraisal. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13073.	4.1	10
33	Tacrolimus Exposure After Liver Transplantation in Randomized Controlled Trials: Too Much for Too Long. <i>American Journal of Transplantation</i> , 2013, 13, 1371-1372.	4.7	9
34	Everolimus is safe within the first month after liver transplantation. <i>Transplant Immunology</i> , 2015, 33, 146-151.	1.2	9
35	Decreased Long-Term Severe Acute Respiratory Syndrome Coronavirus 2-Specific Humoral Immunity in Liver Transplantation Recipients 12 Months After Coronavirus Disease 2019. <i>Liver Transplantation</i> , 2022, 28, 1039-1050.	2.4	9
36	Early predictors of corticosteroid response in acute severe autoimmune hepatitis: a nationwide multicenter study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 131-143.	3.7	9

#	ARTICLE	IF	CITATIONS
37	Real-World Multicenter Experience of Immunosuppression Minimization Among 661 Liver Transplant Recipients. <i>Annals of Transplantation</i> , 2017, 22, 265-275.	0.9	8
38	How much immunosuppression is needed after liver transplantation?. <i>Clinical Transplantation</i> , 2014, 28, 6-7.	1.6	5
39	Histological sub-€classification of cirrhosis using collagen proportionate area in patients with chronic hepatitis C. <i>Liver International</i> , 2021, 41, 1608-1613.	3.9	3
40	Letter: mechanistic target of rapamycin inhibitors as adjuvant therapy for patients with hepatocellular carcinoma undergoing liver transplantation. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 478-479.	3.7	1
41	Increased incidence of COVID-€19 among liver transplant patients in Europe. <i>Transplant International</i> , 2020, 33, 1823-1824.	1.6	1
42	Interaction between tacrolimus, MELD score and acute kidney injury after liver transplantation. Analysis on a large contemporary bicenter meld-€era series. <i>Clinical Transplantation</i> , 2020, 34, e13890.	1.6	1
43	Letter: unknown denominator and misleading conclusions in COVID-€19. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1241-1242.	3.7	1
44	Tacrolimus Trough Concentrations After Liver Transplantation: Back to the Future. <i>Transplantation</i> , 2020, 104, e114-e114.	1.0	0
45	Reply to: ‘Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients’. <i>Journal of Hepatology</i> , 2021, 75, 228-229.	3.7	0